a exercé des fonctions de consultant auprès de Novartis Pharma et a participé en tant qu'orateur à des colloques organisés par Novartis Pharma et Ménarini, investigateur dans des essais cliniques thérapeutiques financés par les laboratoires Amgen, 2014. ,
hôtel, repas) à l'occasion de déplacements pour des congrès médicaux par AstraZeneca, Il a participé en tant qu'orateur à des colloques et symposiums organisés par Novartis, 2014. ,
,
Asthmarelated deaths, Multidiscip Respir Med, vol.11, p.37, 2016. ,
Asthma in France: a review of descriptive epidemiological data, Rev Mal Respir, vol.27, issue.2, pp.151-160, 2009. ,
A summary of the new GINA strategy: a roadmap to asthma control, Eur Respir J, vol.46, issue.3, pp.622-661, 2015. ,
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma, Eur Respir J, vol.43, issue.2, pp.343-73, 2014. ,
Characterization of the severe asthma phenotype by the National Heart Lung, and Blood Institute's Severe Asthma Research Program, J Allergy Clin Immunol, vol.119, issue.2, pp.405-418, 2007. ,
An international observational prospective study to determine the cost of asthma exacerbations (COAX), Respir Med, vol.100, issue.3, pp.434-50, 2006. ,
Severe and difficult-to-treat asthma in adults, N Engl J Med, vol.377, issue.10, pp.965-76, 2017. ,
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program, Am J Respir Crit Care Med, vol.181, issue.4, pp.315-338, 2010. ,
Cluster analysis and clinical asthma phenotypes, Am J Respir Crit Care Med, vol.178, issue.3, pp.218-242, 2008. ,
DOI : 10.1164/rccm.200711-1754oc
URL : http://europepmc.org/articles/pmc3992366?pdf=render
Prognostic value of cluster analysis of severe asthma phenotypes, J Allergy Clin Immunol, vol.134, issue.5, pp.1043-50, 2014. ,
Eosinophilic and noneosinophilic asthma, Am J Respir Crit Care Med, vol.197, issue.1, pp.22-37, 2018. ,
DOI : 10.1164/rccm.201611-2232pp
After asthma: redefining airways diseases, Lancet, vol.391, pp.350-400, 2018. ,
DOI : 10.1016/s0140-6736(17)30879-6
URL : http://spiral.imperial.ac.uk/bitstream/10044/1/51311/6/THELANCET-D-16-01609R2.pdf
Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation, J Clin Invest, vol.106, issue.4, pp.551-560, 2000. ,
DOI : 10.1172/jci8107
URL : http://www.jci.org/articles/view/8107/files/pdf
The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity, J Immunol, vol.164, issue.4, pp.2142-50, 2000. ,
Prevalence of aspirinexacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature, J Allergy Clin Immunol, vol.135, issue.3, 2015. ,
Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma, J Allergy Clin Immunol, vol.116, issue.5, pp.970-975, 2005. ,
Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia, J Allergy Clin Immunol, vol.137, issue.1, 2016. ,
T-helper type 2-driven inflammation defines major subphenotypes of asthma, Am J Respir Crit Care Med, vol.180, issue.5, pp.388-95, 2009. ,
Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature, Eur Respir J, vol.52, issue.4, 2018. ,
Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis, J Allergy Clin Immunol, vol.133, issue.6, 2014. ,
DOI : 10.1016/j.jaci.2013.10.011
URL : http://europepmc.org/articles/pmc4040309?pdf=render
Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids, Thorax, vol.57, issue.10, pp.875-884, 2002. ,
IL-17 in severe asthma. Where do we stand?, Am J Respir Crit Care Med, vol.190, issue.10, pp.1094-101, 2014. ,
Pathophysiology of bronchial smooth muscle remodelling in asthma, Eur Respir J, vol.36, issue.5, pp.1174-84, 2010. ,
Impaired nuclear translocation of the glucocorticoid receptor in corticosteroidinsensitive airway smooth muscle in severe asthma, Am J Respir Crit Care Med, vol.191, issue.1, pp.54-62, 2015. ,
A Transcriptomedriven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED, Am J Respir Crit Care Med, vol.195, issue.4, pp.443-55, 2017. ,
U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, J Allergy Clin Immunol, vol.139, issue.6, pp.1797-807, 2017. ,
T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED, Eur Respir J, vol.49, issue.2, 2017. ,
Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study, Eur Respir J, vol.48, issue.5, pp.1307-1326, 2016. ,
IL-6 pathway upregulation in subgroup of severe asthma is associated with neutrophilia and poor lung function, Clin Exp Allergy, vol.48, issue.4, pp.475-483, 2018. ,
Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma, J Allergy Clin Immunol, vol.141, issue.2, pp.560-70, 2018. ,
Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort, Eur Respir J, vol.46, issue.5, pp.1308-1329, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01969506
Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort, PLoS One, vol.13, issue.9, 2018. ,
Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis, Eur Respir J, vol.51, issue.5, 2018. ,
Reallife" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study, Respir Med, vol.103, issue.11, pp.1633-1675, 2009. ,
Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data, Respir Med, vol.104, issue.9, pp.1381-1386, 2010. ,
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study, Eur Respir J, vol.51, issue.5, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01962427
Mepolizumab treatment in patients with severe eosinophilic asthma, N Engl J Med, vol.371, issue.13, pp.1198-207, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01785638
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma, N Engl J Med, vol.371, issue.13, pp.1189-97, 2014. ,
Longterm efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study, Clin Ther, vol.38, issue.9, 2016. ,
Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment, Allergy, vol.71, issue.9, pp.1335-1379, 2016. ,
DOI : 10.1111/all.12914
URL : https://hal.archives-ouvertes.fr/hal-01785638
Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis, J Allergy Clin Immunol, vol.133, issue.3, pp.921-924, 2014. ,
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials, Lancet Respir Med, vol.3, issue.5, pp.355-66, 2015. ,
DOI : 10.1016/s2213-2600(15)00042-9
Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study, Chest, vol.150, issue.4, pp.789-98, 2016. ,
DOI : 10.1016/j.chest.2016.03.032
URL : https://doi.org/10.1016/j.chest.2016.03.032
Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma, J Allergy Clin Immunol Pract, vol.5, issue.6, 2017. ,
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, Lancet, vol.388, pp.2115-2142, 2016. ,
Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, vol.388, pp.2128-2169, 2016. ,
Oral glucocorticoid-sparing effect of benralizumab in severe asthma, N Engl J Med, vol.376, issue.25, pp.2448-58, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01761510
Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials, Clin Exp Allergy, vol.47, issue.1, pp.129-167, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01821350
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial, Lancet, vol.388, pp.31-44, 2016. ,
Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma, N Engl J Med, vol.378, issue.26, pp.2486-96, 2018. ,
DOI : 10.1056/nejmoa1804092
Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma, N Engl J Med, vol.378, issue.26, pp.2475-85, 2018. ,
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials, Lancet Respir Med, vol.6, issue.7, pp.511-536, 2018. ,
DOI : 10.1016/s2213-2600(18)30184-x
URL : https://lra.le.ac.uk/bitstream/2381/42346/2/Stratos%201%20and%202%20Brightling%20accepted%20pre-publication%20version.pdf
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials, Lancet Respir Med, vol.4, issue.10, pp.781-96, 2016. ,
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma ,
DOI : 10.1183/13993003.00948-2018
, Eur Respir J, vol.53, issue.2, 2019.
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallelgroup, placebo-controlled trial, Lancet Respir Med, vol.4, issue.9, pp.699-707, 2016. ,
Tezepelumab in adults with uncontrolled asthma, N Engl J Med, vol.377, issue.10, pp.936-982, 2017. ,
DOI : 10.1056/nejmoa1704064
Clarithromycin targets neutrophilic airway inflammation in refractory asthma, Am J Respir Crit Care Med, vol.177, issue.2, pp.148-55, 2008. ,
Azithromycin for prevention of exacerbations in severe asthma (AZI-SAST): a multicentre randomised double-blind placebo-controlled trial, Thorax, vol.68, issue.4, pp.322-331, 2013. ,
Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial, Am J Respir Crit Care Med, vol.181, issue.2, pp.116-140, 2010. ,
Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma, J Allergy Clin Immunol, vol.132, issue.6, pp.1295-302, 2014. ,
Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial, BMC Pulm Med, vol.11, issue.8, 2011. ,
Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations, J Allergy Clin Immunol, vol.139, issue.4, pp.1176-85, 2016. ,
Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma, Am J Respir Crit Care Med, vol.190, issue.12, pp.1452-1456, 2014. ,